Vericel (Vericel) Operating Cash Flow per Share : $0.73 (TTM As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Vericel Operating Cash Flow per Share?

Vericel's operating cash flow per share for the three months ended in Mar. 2024 was $0.15. Vericel's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.73.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Vericel was 54.90% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 25.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Vericel's Operating Cash Flow per Share or its related term are showing as below:

VCEL' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -8.6 Med: 18.95 Max: 73.9
Current: 25.9

During the past 13 years, Vericel's highest 3-Year average Operating Cash Flow per Share Growth Rate was 73.90% per year. The lowest was -8.60% per year. And the median was 18.95% per year.

VCEL's 3-Year OCF Growth Rate is ranked better than
75.59% of 1237 companies
in the Biotechnology industry
Industry Median: 3.6 vs VCEL: 25.90

Vericel Operating Cash Flow per Share Historical Data

The historical data trend for Vericel's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Operating Cash Flow per Share Chart

Vericel Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.16

0.37

0.63

0.38

0.74

Vericel Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.17	0.21	0.15	0.21	0.15

Competitive Comparison of Vericel's Operating Cash Flow per Share

For the Biotechnology subindustry, Vericel's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vericel's Price-to-Operating-Cash-Flow falls into.

Vericel Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Vericel's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	35.311	/	47.590
	=	0.74

Vericel's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	7.202	/	48.141
	=	0.15

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.73

Vericel Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Vericel's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel (Vericel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Executives

Dominick Colangelo	director, officer: President and CEO	1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md	director
Paul K Wotton	director	C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn	officer: SVP, General Counsel	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin	officer: Chief Operating Officer	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal	officer: Principal Accounting Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright	director	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr	officer: Chief Financial Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell	officer: VP and Corporate Controller	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel	officer: CFO & VP , Corp. Development	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando	officer: Chief Operating Officer	P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp	10 percent owner	1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019